Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has scheduled its fourth quarter 2024 financial results announcement for March 11, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.
The webcast will be accessible through the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay will be available at the same location approximately two hours after the call's completion and will remain accessible for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VYGR gained 1.28%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.
A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
When will Voyager Therapeutics (VYGR) release Q4 2024 earnings?
What time is Voyager Therapeutics (VYGR) Q4 2024 earnings call?
How can investors access VYGR's Q4 2024 earnings webcast?
How long will VYGR's Q4 2024 earnings call replay be available?
